

DD2 Polyclonal Antibody

Catalog # AP69488

Product Information

| | |
|--------------------------|------------------------|
| Application | WB, IHC-P, IF, ICC, E |
| Primary Accession | P52895 |
| Reactivity | Human, Rat, Mouse |
| Host | Rabbit |
| Clonality | Polyclonal |
| Calculated MW | 36735 |

Additional Information

| | |
|---------------------------|--|
| Gene ID | 1646 |
| Other Names | AKR1C2; DDH2; Aldo-keto reductase family 1 member C2; 3-alpha-HSD3; Chlordecone reductase homolog HAKRD; Dihydrodiol dehydrogenase 2; DD-2; DD2; Dihydrodiol dehydrogenase/bile acid-binding protein; DD/BABP; Trans-1; 2-dihydrobenzene-1, 2-diol |
| Dilution | WB~~Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. ELISA: 1/20000. Not yet tested in other applications. IHC-P~~N/A IF~~1:50~200 ICC~~N/A E~~N/A |
| Format | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% (W/V) sodium azide. |
| Storage Conditions | -20°C |

Protein Information

| | |
|-----------------|--|
| Name | AKR1C2 {ECO:0000303 PubMed:9716498} |
| Synonyms | DDH2 |
| Function | Cytosolic aldo-keto reductase that catalyzes NADPH-dependent reduction of ketosteroids to hydroxysteroids. Displays broad substrate specificity with distinct positional and stereochemistry, primarily generating 3alpha-hydroxysteroids, but also 3beta-, 17beta- and 20alpha-hydroxysteroids (PubMed: 8920937 , PubMed: 9716498 , PubMed: 10998348 , PubMed: 12416991 , PubMed: 11995921 , PubMed: 12604236 , PubMed: 14672942 , PubMed: 19218247 , PubMed: 21802064 , PubMed: 11514561 , PubMed: 15929998 , PubMed: 17034817 , PubMed: 17442338 , PubMed: 24434280). Required for male sex determination as a component of the 'backdoor' androgen biosynthesis pathway that generates 5alpha-dihydrotestosterone (5alpha-DHT) via pregnanes. Acts together with AKR1C4 to convert 5alpha-dihydroprogesterone (5alpha-DHP) to |

3alpha-hydroxy-5alpha-pregnan-20-one (3alpha,5alpha-THP/allopregnanolone), leading to 5alpha-DHT secretion necessary for embryonic gonad differentiation into testis (PubMed:[12416991](#), PubMed:[21802064](#)). In androgen catabolism, may predominantly act as a phase I enzyme by introducing a hydroxyl group prior to conjugation. It can nevertheless participate in the alternative phase II pathway by directly reducing sulfate- or glucuronide-conjugated androgens (PubMed:[10998348](#), PubMed:[11514561](#), PubMed:[14672942](#), PubMed:[15929998](#), PubMed:[19218247](#), PubMed:[24434280](#)). In neurosteroid biosynthesis, may preferentially reduce 5alpha-dihydroprogesterone (5-alpha-DHP) and 5alpha-dihydrodeoxycorticosterone (5-alpha-DHDOC) precursors to 3alpha-hydroxy-5alpha-pregnan-20-one (3alpha,5alpha-THP/allopregnanolone) and 3alpha,21-dihydroxy-5alpha-pregnane-20-one (3alpha,5alpha-THDOC) neuroactive steroids known to alter neural excitability via allosteric activation of gamma-aminobutyric acid type A receptors (GABAAR) (PubMed:[11995921](#), PubMed:[12416991](#), PubMed:[12604236](#)). Regulates ligand availability for steroid hormone receptors. Catalyzes the inactivation of 5alpha-DHT and progesterone converting them into 3alpha/beta-androstane diols and (20S)-hydroxypregn-4-en-3-one, respectively (PubMed:[10998348](#), PubMed:[24434280](#)). Can form 17beta-hydroxysteroids such as testosterone and estradiol albeit with lower efficiency when compared to AKR1C3 (PubMed:[10998348](#)). May contribute to the metabolism of adrenal-derived androgens via reduction of 11-keto-5alpha-androstane-3,17-dione (11K-Adione) into 11-ketoandrosterone (11KAST) and of 11-ketodihydrotestosterone (11KDHT) into 11-keto-5alpha-androstane-3alpha/beta,17beta-diol (11K-A3alphadiol) (PubMed:[31926269](#)). May also play a role in prostaglandin (PG) metabolism by reducing PGD2 to 11beta-PGF2 (PubMed:[9716498](#)). Also able to metabolize xenobiotics (S)-indan-1-ol and trans-1,2-dihydrobenzene-1,2-diols (PubMed:[8573067](#), PubMed:[9716498](#)). In vitro can efficiently catalyze bidirectional conversion between ketosteroids and hydroxysteroids using NADPH/NADP(+) or NADH/NAD(+) as cofactors. In vivo however, the reductase activity prevails since the major reducing cofactor NADPH inhibits NAD(+)-dependent oxidase activity (PubMed:[14672942](#), PubMed:[21802064](#)).

Cellular Location

Cytoplasm, cytosol.

Tissue Location


Expressed in fetal testes. Expressed in fetal and adult adrenal glands.

Background

Works in concert with the 5-alpha/5-beta-steroid reductases to convert steroid hormones into the 3-alpha/5-alpha and 3-alpha/5-beta-tetrahydrosteroids. Catalyzes the inactivation of the most potent androgen 5-alpha-dihydrotestosterone (5-alpha-DHT) to 5-alpha-androstane-3-alpha,17-beta-diol (3-alpha-diol). Has a high bile-binding ability.

Images

Western Blot analysis of COLO cells using DD2 Polyclonal Antibody



Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.